Mepolizumab and benralizumab are both potent targets of the interlukin-5 pathway with the ability to significantly reduce eosinophil counts, according to new research published in Allergy, Asthma & ...

Please provide your email address to receive an email when new articles are posted on . Outcomes improved with mepolizumab regardless of one or more past surgeries. For surgery risk and oral ...

While mepolizumab has proven safe and effective for severe asthma, how has it performed in treating those with allergic vs non-allergic asthma? Mepolizumab use significantly reduced the use of oral ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window SAN ANTONIO -- ...

Severe asthma treatment with the interleukin-5 antagonist mepolizumab (Nucala) reduced the need to take oral corticosteroids in patients who had depended on steroids to control symptoms, according to ...

GlaxoSmithKline plc (LSE/NYSE: GSK) today announced that it has filed regulatory submissions in the USA and Europe for mepolizumab for approval as a maintenance treatment for patients with severe ...

Mepolizumab was found to reduce nasal polyp size and nasal obstruction in patients with chronic rhinosinusitis with nasal polyps regardless of the presence of potentially exacerbating comorbidities.

Please provide your email address to receive an email when new articles are posted on . Mepolizumab reduced polyp size and nasal obstructions in patients with chronic rhinosinusitis with nasal polyps ...

nasal polyps illustration The phase 3 SYNAPSE clinical trial evaluated the efficacy of mepolizumab in improving sense of smell in patients with chronic rhinosinusitis with nasal polyps. The monoclonal ...

Eosinophil White Blood Cell What is the difference in efficacy between mepolizumab and benralizumab, 2 biologics approved for the treatment of severe eosinophilic asthma? Mepolizumab and benralizumab ...